13 Feb CHO Plus
Larry Forman, CEO
April 28 | 10:45am | Salone dei Cavalieri, Section 1
San Francisco, CA
(Private)
CHO Plus is driving down the cost of manufacturing AAV viral vectors while also making it possible to produce unlimited doses for treating common diseases. We have a dual approach: (a) We engineer HEK-293 cells for up to 20-fold higher productivity (4 x 10^16 vg/liter) and up to 2-fold higher full capsids (up to 55% full) before purification. Further advances are anticipated. (b) We have developed non-leaky, inducible promotors that allow for normal growth before induction, and full production with high percent-full capsids after induction. Scale-up to 10,000 liters is possible, using small molecule inducers. This innovation eliminates the need for transient transfection (and the costly DNA), and it allows for the manufacture of millions of gene therapy doses. We will present our work, and discuss its value—to pharmaceutical companies, and to the patients who need these therapies.
